Cubist Systematic Strategies’s Pliant Therapeutics PLRX Stock Holding History

Cubist Systematic Strategies’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$80.5K	Sell	54,367 -213,986	-80%	-$327K	﹤0.01%	2799
2025 Q2	$311K	Buy	+268,353	New	+$379K	﹤0.01%	2453
2023 Q3	–	Sell	-60,883	Closed	-$1.1M	–	3799
2023 Q2	$1.1M	Sell	60,883 -180,455	-75%	-$4.27M	0.01%	1895
2023 Q1	$6.42M	Buy	241,338 +178,608	+285%	+$5.09M	0.04%	758
2022 Q4	$1.21M	Sell	62,730 -39,905	-39%	-$834K	0.01%	2269
2022 Q3	$2.14M	Buy	102,635 +51,315	+100%	+$982K	0.01%	1942
2022 Q2	$411K	Buy	51,320 +32,906	+179%	+$211K	﹤0.01%	3204
2022 Q1	$129K	Buy	18,414 +7,539	+69%	+$76.9K	﹤0.01%	3173
2021 Q4	$147K	Buy	+10,875	New	+$173K	﹤0.01%	3112

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Cubist Systematic Strategies's PLRX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Pliant Therapeutics (PLRX) stake by 80% in Q3 2025, selling an estimated $327K and leaving 54,367 shares worth $80.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2799.

Cubist Systematic Strategies first reported a position in PLRX in Q4 2021 and has held it in 9 quarters since. The position peaked at $6.42M in Q1 2023. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

Cubist Systematic Strategies held 54,367 shares of Pliant Therapeutics worth $80.5K as of Q3 2025.
Cubist Systematic Strategies sold 213,986 Pliant Therapeutics shares in Q3 2025, an estimated $327K.
Pliant Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2799 holding.
Cubist Systematic Strategies first reported a position in Pliant Therapeutics in Q4 2021 and has held it in 9 quarters since.
Cubist Systematic Strategies's Pliant Therapeutics position peaked at $6.42M in Q1 2023.
99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.